Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for June, 2013

Cytokinetics: Another Positive Deal for Shareholders, This Time with Astellas (CYTK, $11.81)

Cytokinetics (CYTK) has completed its second meaningful deal in two weeks. Today they announced a deal with Astellas (ALPMY) and on June 12, they announced a deal that allows Amgen to develop omecamtiv mecarbil in Japan. Today’s deal brings in $16 million as an upfront milestone and the Amgen (AMGN) deal brought in $15 million […]

Cytokinetics (CYTK, $1.40) Receives a Vote of Confidence from Amgen

Cytokinetics (CYTK) has announced an expansion of the partnering agreement with Amgen (AMGN) for omecamtiv mecarbil, the Company’s lead product which is being developed for congestive heart failure. In the original agreement, rights to omecamtiv in Japan were not included. The expansion gives Amgen rights in Japan as well. Cytokinetics will receive $25 million which […]

Northwest Biotherapeutics ($3.44): M.D. Anderson’s Lead Role in DCVax Direct Trial is Encouraging

Northwest Biotherapeutics (NWBO) announced today that the phase I/II trial of DCVax Direct has been initiated at M.D. Anderson Cancer Center in Houston, Texas; this is one of the premier centers for cancer drug development in the US. Additional sites in the US and UK should open soon. I view the lead role of M.D. […]

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an indication that we have reached the point at which society will collectively decide to declare a war on resistant bacteria that could provide the same impetus to the development of anti-microbial drugs that the […]

SmithOnStocks Opines on Biotechnology Stocks, June 10, 2013

Introduction This week’s edition of SmithOnStocks Opines includes brief comments on news concerning ImmunoCellular Therapeutics (IMUC) and Cadence (CADX), last week and have highlighted an upcoming presentation that could be a boost to Neuralstem’s (CUR) stock. ImmunoCellular Therapeutics (IMUC): The Company announced that the phase II trial of ICT-107 had reached an interim point that […]

SmithOnStocks Opines on Biotechnology Stocks, June 2, 2013

Overview of This Week’s Report This week I published a major report on Alimera Sciences and pSivida which led to my recommendation of pSivida. I also comment on Neuralstem’s press release on a rat study modeling the use of NSI-566 neural stem cells in an acute spinal cord injury which showed some encouraging data. The […]